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PChord-TAV strain distribution was up to 42% lower than for fabricated chordless valves.
Chord-TAVs exhibited satisfactory hydrodynamics for size 23 valves. Initial AWT
testing data indicated that strain reduction continues following cyclic loading (Fig.1). O
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SConclusions: Chord-TAVs with chordal reinforcement provided structural support
that greatly reduced leaﬂet stress and strain. Such reduction will improve valve
performance and overall valve durability.
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Background: A strong component of predicted mortality in scoring systems is
advanced age, however, outcomes data in nonagenarians (age >90 years) is lacking.
We evaluated surgical outcomes after aortic valve replacement (AVR) in nonage-
narians at our institution over an 11-year period.
Methods: Demographics, procedural details, and in-hospital outcomes were retro-
spectively analyzed on 119 patients with severe aortic stenosis (AS) who underwent
AVR or AVR+concomitant surgery between 2001 and 2012. Mean duration of
follow-up was 915832 days.
Results: The average age was 91.71.9 years (range 90-97) and mean STS score was
8.95.7. Over 98% of patients met echocardiographic criteria for severe AS (mean
gradient 45.016.1 mmHg, aortic valve area 0.660.2 cm2), had an ejection fraction
of 49.811.8%, and 47% underwent an isolated AVR. Though average length of stay
was longer than expected, rates of prolonged ventilation (16.8%), new atrial ﬁbrilla-
tion (43.7%), stroke (0.8%), and renal failure (5.9%) were acceptable. Three patients
(2.5%) required reoperation for bleeding. Overall 30 day or in-hospital mortality was
7.6%, and multivariate predictors of mortality at 1 years included prior myocardial
infarction (HR 2.79, 95% CI: 1.21-6.45, p¼0.016), obstructive lung disease (HR 3.90,
95% CI: 1.66-9.15, p¼0.025), and diabetes (HR 2.77, 95% CI: 1.08-7.07, p¼0.033).
Observed mortality at 30 days was lower than expected (observed/expected¼0.85).Table 1. Demographics and Procedural Outcomes
Concomitant surgery status, n (%)
Isolated AVR 56 (47.1%)
AVR + CABG 47 (39.5%)
AVR + MVR 10 (8.4%)
AVR + Other 6 (5.0%)
Duration of hospital stay in days
Overall 16.511.7
Isolated AVR 13.99.1
AVR + any surgery 18.713.2
Re-operation for bleeding, n (%) 3 (2.5%)
30-day or in-hospital mortality, n (%) 9 (7.6%)
Cumulative mortality at 1 year
Isolated AVR 16.1%
AVR+any surgery 25.4%
AVR- aortic valve replacement, CABG- coronary artery bypass grafting, MVR-mitral valve
replacement.Conclusions: Excellent procedural and long-term outcomes can be achieved in
nonagenarians, and age alone should not be a contraindication for valve replacementJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrin select populations. This sample cohort validates the feasibility of a primary oper-
ative strategy in elderly patients with AS and acceptable risk proﬁles.
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Background: The incidence of transcatheter heart valve (THV) device malposition is
higher during aortic valve-in-valve implantation (VinV). We aimed to evaluate for
correlates for this complication.
Methods: Aortic VinV procedures included in the Global Valve-in-Valve Registry
were investigated (459 procedures, 246 Edwards SAPIEN and 213 CoreValve).
Results: THV device malposition occurred in 50 cases (10.9%) resulting in attempted
device retreival (10.3% of CoreValve implantations) and second THV device
implantation (7.5% CoreValve vs. 4.1% Edwards SAPIEN, p¼0.052). Device
malposition was more common during CoreValve VinV procedures(16.4% vs. 6.1%,
Edwards SAPIEN, p¼0.0004). In Edwards SAPIEN VinV procedures there was no
difference in malposition rate between transfemoral and transapical procedures (4.1%
vs. 7%, p¼0.39). Device malposition was more common in procedures performed
early in the learning-curve (14.4% vs. 9% after the seventh case per center, p¼0.046),
with regurgitant bioprostheses (13.3% vs. 7.2% in bioprostheses with isolated
stenosis, p¼0.04) and with stentless and Mosaic stented valves (16.1%,14.0% vs.
9.0% in non-Mosaic stented valves, p¼0.04).
Conclusions: Device malposition is common during aortic VinV procedures and may
result implantation of a second THV device. Malposition was more common when
performed early in the learning curve, with CoreValve VinV procedures and with
regurgitant, stentless and Mosaic bioprostheses.
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Background: Low-Flow Low-Gradient (LF-LG) or "Paradoxical Aortic Stenosis" is
a rarely encountered clinical entity with limited data on clinical outcomes after
surgical (SAVR) or trans-catheter aortic valve (TAVI) replacement. We conducted
a meta-analysis of all the studies comparing all-cause mortality after aortic valve
replacement in LF-LG AS in comparison to medical therapy alone.
Methods: A thorough PubMed (time-unlimited till 06/01/2013) search revealed 5
studies comparing TAVI/SAVR outcomes in LF-LG aortic stenosis (mean gradient
<40mmHg; stroke volume index <35ml/m2). Primary clinical endpoint was all-cause
mortality at 2 year follow-up. Odds ratio (OR) and conﬁdence interval (CI) were
estimated using the random effects model.
Results: A total of 607 patients (SAVR/TAVI 263; medical therapy 344) were
included in the analysis. Baseline characteristics of these patients in valve
replacement and medical therapy arms were comparable. At 2-year follow-up,
SAVR/TAVI was associated with lower all-cause mortality (24.3% vs. 55.8%; OR
0.23; 95% CI 0.15 – 0.36). This corresponds to an absolute risk reduction of 31.5%
and a Number Needed to Treat 3.55 to save one life.acts/POSTER/Aortic Valve Disease and Treatment B231
